160 related articles for article (PubMed ID: 37410852)
21. Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).
Drake MJ; Canham L; Cotterill N; Delgado D; Homewood J; Inglis K; Johnson L; Kisanga MC; Owen D; White P; Cottrell D
BMC Neurol; 2018 Aug; 18(1):107. PubMed ID: 30081859
[TBL] [Abstract][Full Text] [Related]
22. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
Chamarthi B; Cincotta AH
Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
[TBL] [Abstract][Full Text] [Related]
24. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
26. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial.
Raygan F; Ostadmohammadi V; Bahmani F; Reiter RJ; Asemi Z
Clin Nutr; 2019 Feb; 38(1):191-196. PubMed ID: 29275919
[TBL] [Abstract][Full Text] [Related]
27. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Ziaei A; Davoodian P; Dadvand H; Safa O; Hassanipour S; Omidi M; Masjedi M; Mahmoudikia F; Rafiee B; Fathalipour M
Trials; 2020 Oct; 21(1):882. PubMed ID: 33106171
[TBL] [Abstract][Full Text] [Related]
29. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
30. Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes-A randomized placebo-controlled crossover trial.
Lauritzen ES; Kampmann U; Pedersen MGB; Christensen LL; Jessen N; Møller N; Støy J
J Pineal Res; 2022 Aug; 73(1):e12809. PubMed ID: 35619221
[TBL] [Abstract][Full Text] [Related]
31. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
32. Improving Self-management of Type 2 Diabetes in Latinx Patients: Protocol for a Sequential Multiple Assignment Randomized Trial Involving Community Health Workers, Registered Nurses, and Family Members.
Kopelowicz A; Nandy K; Ruiz ME; Polzin R; Kurator K; Wali S
JMIR Res Protoc; 2023 Jan; 12():e44793. PubMed ID: 36645708
[TBL] [Abstract][Full Text] [Related]
33. Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial.
Bazyar H; Zare Javid A; Bavi Behbahani H; Moradi F; Moradi Poode B; Amiri P
Trials; 2021 Mar; 22(1):231. PubMed ID: 33766084
[TBL] [Abstract][Full Text] [Related]
34. Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial.
Chang YS; Lin MH; Lee JH; Lee PL; Dai YS; Chu KH; Sun C; Lin YT; Wang LC; Yu HH; Yang YH; Chen CA; Wan KS; Chiang BL
JAMA Pediatr; 2016 Jan; 170(1):35-42. PubMed ID: 26569624
[TBL] [Abstract][Full Text] [Related]
35. A Series of Remote Melatonin Supplement Interventions for Poor Sleep: Protocol for a Feasibility Pilot Study for a Series of Personalized (N-of-1) Trials.
Butler M; D'Angelo S; Perrin A; Rodillas J; Miller D; Arader L; Chandereng T; Cheung YK; Shechter A; Davidson KW
JMIR Res Protoc; 2023 Aug; 12():e45313. PubMed ID: 37535419
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the effectiveness of cinnamon (Cinnamomum verum) in the reduction of glycemic and lipidic levels of adults with type 2 diabetes: A study protocol.
Neto JCGL; Damasceno MMC; Ciol MA; de Freitas RWJF; de Araújo MFM; de Souza Teixeira CR; Carvalho GCN; de Siqueira Coelho Lisboa KW; de Souza DF; de Menezes Nogueira J; Marques RLL; Alencar AMPG
Medicine (Baltimore); 2020 Jan; 99(1):e18553. PubMed ID: 31895796
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of American ginseng (Panax quinquefolius L.) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial.
Vuksan V; Xu ZZ; Jovanovski E; Jenkins AL; Beljan-Zdravkovic U; Sievenpiper JL; Mark Stavro P; Zurbau A; Duvnjak L; Li MZC
Eur J Nutr; 2019 Apr; 58(3):1237-1245. PubMed ID: 29478187
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
[TBL] [Abstract][Full Text] [Related]
39. Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
Parthan G; Bhansali S; Kurpad AV; Walia R; Bhat K; Bhansali A
BMC Pharmacol Toxicol; 2018 Jul; 19(1):38. PubMed ID: 29970184
[TBL] [Abstract][Full Text] [Related]
40. The use of MElatonin in children with neurodevelopmental disorders and impaired sleep: a randomised, double-blind, placebo-controlled, parallel study (MENDS).
Appleton RE; Jones AP; Gamble C; Williamson PR; Wiggs L; Montgomery P; Sutcliffe A; Barker C; Gringras P
Health Technol Assess; 2012; 16(40):i-239. PubMed ID: 23098680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
